CORE--MOLECULAR BIOLOGY

分子生物学核心在过去的九年里一直在运行 并为众多分子提供了最先进的方法学 生物技术以及重组蛋白的表达和 净化。分子生物学核心的主要目标是： 1.收集和维护合适的质粒载体和宿主 HIV/SIV及相关重组蛋白的表达。 2.为构建高效、高效的重组表达载体提供服务 HIV/SIV及其相关蛋白的水平表达。 3.为HIV/SIV及相关蛋白的纯化提供服务。 4.建立携带HIV/SIV基因的现场质粒库 以及重组HIV/SIV蛋白。 5.为建设传染性HIV/SIV前病毒提供服务 包含目标基因特定突变的克隆。 6.培训人员以协助不同阶段的质粒 重组蛋白的构建、表达和纯化 促进技术转让的目的。 分子生物学核心平均协助了CFAR的30多名成员 在上一次供资期间，每年都会出现这种情况。核心指数平均超过 在过去3年半内每年按存储容量使用计费30,000美元，总计 本供资期间迄今的122677美元。分子生物学 CORE为UAB CFAR成员提供关键试剂和专业知识 他们资助了个人R01赠款，并参与了UAB 国家合作疫苗开发与国家合作药物 探索小组。因此，对这一设施的支持有助于 在不同领域工作的众多调查人员继续取得成功 目前在UAB进行的艾滋病毒致病机理、疫苗和药物研究。

The Molecular Biology Core has been in operation for the past nine years and has provided state-of-the-art methodologies for numerous molecular biological techniques as well as recombinant protein expression and purification. The major goals of the Molecular Biology Core are: 1. To collect and maintain suitable plasmid vectors and host for expression of HIV/SIV and related recombinant proteins. 2. To provide a service for construction of recombinant plasmids and high level expression of HIV/SIV and related proteins. 3. To provide a service for purification of HIV/SIV and related proteins. 4. To establish an on-site repository for plasmids with HIV/SIV genes as well as recombinant HIV/SIV proteins. 5. To provide a service for construction of infectious HIV/SIV proviral clones containing defined mutations in genes of interest. 6. To train personnel to assist in the various phases of plasmid construction and expression/purification of recombinant proteins for the purpose of facilitating technology transfer. The Molecular Biology Core has assisted, on average, over 30 CFAR members per year during the last funding period. The Core has averaged over $30,000 per year in chargebacks over the last 3-1/2 years with a total of $122,677 to date for the current funding period. The Molecular Biology Core has provided critical reagents and expertise to UAB CFAR members which have funded individual R01 grants as well as participate in the UAB National Cooperative Vaccine Development, and National Cooperative Drug Discovery Group. Support of this facility is thus instrumental for the continued success of numerous investigators working in different areas of HIV pathogenesis, vaccine and drug studies currently conducted at UAB.